Hormonal
Pitavastatin 4mg daily increases the risk of new-onset diabetes in people with HIV, but this effect is clinically significant primarily in individuals with multiple baseline metabolic risk factors (obesity, pre-diabetes, or metabolic syndrome).
If you have HIV and are considering statins for heart health, discuss your metabolic risk factors (weight, blood sugar) with your doctor. If you are healthy weight and have normal blood sugar, your risk of developing diabetes from the statin is very low. If you have existing metabolic risks, your doctor may monitor your blood sugar more closely or suggest lifestyle interventions to mitigate this small risk.
A clinically significant effect of pitavastatin on DM was seen primarily among those with multiple risk factors for DM at entry.
Why this rating
Large, global, randomized, double-blind, placebo-controlled trial (REPRIEVE) with long follow-up.
Source
Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention
Kathleen V. Fitch et al. · Annals of Internal Medicine · 2024
DOI 10.7326/annals-24-00944
More from this paper
- Baseline metabolic risk factors, specifically pre-diabetes, obesity (high BMI), and metabolic syndrome components, are the strongest predictors of new-onset diabetes in people with HIV, regardless of statin treatment.Strong
- Race and geographic region significantly modify the risk of new-onset diabetes in people with HIV, with higher rates observed in South Asia and among Black or African American individuals in high-income regions.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →